Ondansetron Teva

Ondansetron, the active ingredient in Ondansetron Teva, is a 5‑HT3 receptor antagonist presented as an oral dosage form for oral use. It is employed to prevent nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery in adult patients. The medication is indicated for patients undergoing emetogenic treatments and is available by prescription.

GNH USA supplies Ondansetron Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, ensuring consistent quality and regulatory compliance across global markets.

Ondansetron Teva is used to manage nausea and vomiting by blocking serotonin receptors that trigger the emetic response in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: provides prophylaxis and treatment of acute and delayed nausea and vomiting in patients receiving moderately to highly emetogenic chemotherapy. - Radiotherapy‑induced nausea and vomiting: reduces the frequency and severity of nausea and vomiting that can occur during or after radiation therapy, especially when combined with chemotherapy. - Postoperative nausea and vomiting: administered before surgery to lessen the incidence of nausea and vomiting in the immediate postoperative period.

Ondansetron may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT interval prolongation, potentially leading to irregular heartbeat. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or visual disturbances.

When prescribing Ondansetron Teva, clinicians should consider several precautionary measures to ensure safe use. - Assess cardiac risk: evaluate baseline ECG in patients with known QT prolongation or electrolyte disturbances. - Review concomitant drugs: avoid co‑administration with other QT‑prolonging agents when possible. - Monitor hepatic function: adjust use in patients with severe liver impairment. - Use caution in pregnancy: consider risk‑benefit ratio as safety data are limited. - Adjust for renal impairment: dose may need modification in severe renal dysfunction. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Ondansetron Teva can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Apomorphine: may cause profound hypotension and loss of consciousness. - Certain anti‑arrhythmics (e.g., amiodarone, quinidine): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely): - Other QT‑prolonging drugs (e.g., fluoroquinolones, macrolide antibiotics): may require ECG monitoring. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): potential for serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure.